SURMOUNT-2: Tirzepatide achieved up to 15.7% weight loss owenhaskins Apr 28, 2023 4 min read Seventy-two week outcomes from the SURMOUNT-2 trial has revealed that tirzepatide (10mg and 15mg) achieved superior weight loss compared to placebo, meeting both co-primary objectives and all key secondary objectives for tirzepatide compared to placebo for both estimandsi
Start your intake Anatomy of Safe Semaglutide Injection Sites on the Arm The outer back portion of the upper armroughly between the shoulder and elbow, in the middle third of the armoffers the most reliable subcutaneous tissue depth for semaglutide absorption
Since each patient is different, a customized approach is recommended
Obesity medicine is not a one-size-fits-all discipline, and as Eli Lilly employees and obesity medicine specialists continue to explore and understand tirzepatides effects, patients too must adapt to a holistic approach towards health
doi: 10.3390/JOX14040084 206 JuanCAde la LastraJMPPlouFJPrez-LebeaE
Garbuzova-Davis S, Ehrhart J, Sanberg PR, Borlongan CV